CME online

in association with the 16th WCIRDC

CHF, the Next Frontier in Diabetes: The Role of SGLT2 Inhibitors in
its Prevention and Management

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:
This CME online educational activity is approved for a maximum of 2 AMA PRA Category 2 Credit(s).
Accreditation period: January 1, 2019 - January 1, 2020

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

Agenda

Introduction Pre- CME Questions
Yehuda Handelsman, MD

Epidemiology of CHF in Diabetes Differentiating HFrEF and HFpEF
Biykem Bozkurt, MD, PhD

The Role of the Kidney in CHF- The Cardio-Renal Syndrome
Matthew R. Weir, MD

Diabetes CVOT impact on CHF in Diabetes
Mikhail Kosiborod, MD

The Contemporary Approach to the Management of CHF in DM & Non-DM
Robert J. Chilton, DO

Panel Discussion Q&A The future of the Diagnoses and Management of CHF.
Faculty: Biykem Bozkurt, MD, PhD • Robert J. Chilton, DO • Ralph A. DeFronzo, MD • Mikhail Kosiborod MD • Sanjay Kaul, MD • Matthew R. Weir, MD
Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACP, FNLA, MACE Chair

Chair & Program Director
Medical Director & Principal Investigator
Metabolic Institute of America
Chair & Founder, ICIR
Chair & Founder International Lipid Forum
Tarzana, California

Biykem Bozkurt, MD, PhD FHFSA, FACC, FAHA

Professor of Medicine
The Mary and Gordon Cain &
W.A. “Tex” and Deborah Moncrief, Jr., Chair
Medical Care Line Executive
DeBakey VA Medical Center
Director, Winters Center for Heart Failure Research
Associate Director, Cardiovascular Research
Vice-Chair of Medicine
Baylor College of Medicine
Houston, Texas

Robert J. Chilton, DO, FACC

Professor of Medicine
Department of Medicine
Division of Cardiology The University of Texas
Health Science Center
San Antonio, Texas

Ralph A. DeFronzo, MD

Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio (UTHSCSA)
Deputy Director Texas Diabetes Institute San Antonio, Texas

Sanjay Kaul MD, FACC, FAHA

Division of Cardiology
Cedars-Sinai Medical Center
David Geffen School of Medicine
Ronald Reagan UCLA Medical Center
Fellow, American Heart Association
Fellow, ACC
Los Angeles, California

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine,
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Kansas City, Missouri

Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine University of Maryland
School of Medicine
Baltimore, Maryland

Program Description

Heart failure (HF) is on the rise and poses a growing challenge to patients with diabetes and their healthcare teams. Both diabetes and renal impairment contribute to Hf risk, and Hf in turn can worsen diabetes and renal outcomes. Another hurdle clinicians face is the recognition and differential diagnosis of Hf with preserved vs reduced ejection fraction (HfpEf and HfrEF). HfpEF, which commonly affects patients with metabolic diseases, has a different presentation and may respond to treatment differently than HfrEF. Clinicians must also understand the effects of different antihyperglycemic therapies on HF, including which agents are likey to provide a benefit and which may increase HF risks. This satellite symposium will focus on the diagnosis and management of heart failure in patients with diabetes and will help clinicians sort through the evidence and identify the best approaches for individual patients.


Learning Objectives

Upon completion of this meeting, participants should be able to:

  • Explain differences in the pathophysiologic development and differential diagnosis of heart failure with reduced vs preserved ejection fraction
  • Describe how the cardio-renal syndrome contributes to the development of heart failure risk in diabetes
  • Compare and contrast the effects of different antihyperglycemic agents on heart failure risk
  • Design therapeutic regimens to suit the needs of individual patients with and without diabetes who have have comorbid HFpEF or HFrEF

    • Target Audience

    This educational initiative is designed for endocrinologists, cardiologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI, Inc and Metabolic Endocrine Education Foundation (MEEF).

    PESI Inc is accredited by the ACCME to provide continuing medical education for physicians.

    PESI Inc designated this live educational activity for a maximum of 2 AMA PRA Category 2 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

    This is a CME Program Supported by an Educational Grant from AstraZeneca
    Jointly Provided by    : MEEF & PESI